Graphite launches with $45M series A to use CRISPR-Cas9 for targeted gene integration

Matthew Porteus’ latest gene editing play Graphite Bio launched with a $45 million series A round and a technology to tackle one of the biggest challenges in CRISPR-based gene editing: inserting corrected gene sequences.

Versant Ventures led the company’s series A round announced on Wednesday, and Samsara BioCapital contributed $15 million...